Cosmos Health Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Grigorios Siokas
- Full Time Employees
- 163
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 5 Agiou Georgiou Str, Pilea Thessaloniki IL Greece 55438
- IPO Date
- Jul 23, 2010
- CIK
- 0001474167
- Website
- cosmoshealthinc.com
- Similar Companies
- Business
- Cosmos Health Inc. (NASDAQ: COSM) operates as a diversified, vertically integrated global pharmaceutical holding company that develops, manufactures, and distributes proprietary nutraceuticals, branded generics, over-the-counter medications, medical devices, cosmetics, food supplements, and healthcare products; its core brands include Sky Premium Life, Mediterranation, bio-bebe, C-Sept, and C-Scrub, with additional offerings in vitamins, minerals, herbal extracts, and specialized root extracts produced under European Good Manufacturing Practices through subsidiary Cana Laboratories S.A. The company serves retail pharmacies, wholesale distributors, hospitals, and healthcare providers with a broad portfolio encompassing prescription drugs, OTC products, and nutraceuticals targeted at wellness, prevention, and therapeutic needs in areas such as obesity, diabetes, and cancer. Founded in 2009 and headquartered in Chicago, Illinois, Cosmos Health maintains operations across Europe, the UK, Asia, and North America, with key facilities in Thessaloniki and Athens, Greece, and Harlow, UK; it also provides healthcare distribution through EU and UK subsidiaries and has expanded into telehealth via its acquisition of ZipDoctor, Inc. in Texas, USA. In recent developments, Cosmos Health launched a long-term strategic partnership with Prime Ledger LLC on December 3, 2025, to manage its $300 million treasury facility, implement blockchain-based controls and reporting, and tokenize high-value intellectual property assets. The company commenced U.S. operations in September 2025 with its Sky Premium Life brand, leveraging local manufacturing to enter the $164 billion nutraceuticals market, while advancing R&D initiatives including AI-enhanced drug repurposing, nanotechnology for dietary supplements, and proprietary complex generics. CEO Greg Siokas increased his ownership by acquiring 301,101 shares in late 2025, signaling confidence amid record Q3 2025 results, and the firm diversified investments with Ethereum purchases totaling $2 million.
Cosmos Health Expands Pharma Cell Partnership in Albania with Annualized Orders Projected to Exceed 54,000 Units
Cosmos Health Share Buyback Expands to 5.11 Million Shares; Continues Open Market Repurchases
Cosmos Health Share Buyback Surpasses $1 Million, Reaching 4.84 Million Shares; Continues Open Market Repurchases
Cosmos Health Share Buyback Surpasses 4.5 Million Shares; Continues Open Market Repurchases
Cosmos Health Share Buyback Surpasses 4.5 Million Shares; Continues Open Market Repurchases
Cosmos Health Share Buyback Expands to 4.49 Million Shares; Continues Open Market Repurchases
Cosmos Health Share Buyback Reaches 4.36 Million Shares; Continues Open Market Repurchases
Cosmos Health Accelerates Prescription Medicine Strategy with Libytec Partnership to Commercialize DIABIT-IS X in Greece
Cosmos Health Accelerates Prescription Medicine Strategy with Libytec Partnership to Commercialize DIABIT-IS X in Greece
Cosmos Health Launches Subscription Model
Cosmos Health Launches Subscription Model
Cosmos Health Expands Share Buyback to 4.14 Million Shares; Continues Open Market Repurchases
Cosmos Health Share Buyback Surpasses 4 Million Shares; Continues Open Market Repurchases
Cosmos Health Share Buyback Expands to 3.87 Million Shares; Continues Open Market Repurchases
Cosmos Health Share Buyback Expands to 3.87 Million Shares; Continues Open Market Repurchases
Cosmos Health Reports Preliminary Record Q2 and H1 2026 Revenue, Up Over 30% Year-Over-Year; Continues Open Market Share Repurchases
Cosmos Health Share Buyback Increases to 3.64 Million Shares; Continues Open Market Purchases
Cosmos Health Expands Buyback to 3.42 Million Shares With Additional 770,000-Share Repurchase; Continues Open Market Purchases
Cosmos Health Completes Initial Repurchase of 2.65 Million Shares for $500,000; Continues Open Market Buybacks at Current Pace
Cosmos Health Completes Initial Repurchase of 2.65 Million Shares for $500,000; Continues Open Market Buybacks at Current Pace